When was lvad invented

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 17, 2026

Quick Answer: The left ventricular assist device (LVAD) was first developed in the 1960s, with the first successful implantation occurring in 1966 by Dr. Michael DeBakey using a prototype device. Modern continuous-flow LVADs emerged in the early 2000s, with the HeartMate II receiving FDA approval in 2010.

Key Facts

The first LVAD prototype was tested in 1966 by Dr. Michael DeBakey
The first clinical LVAD implant was performed in 1984 at The Methodist Hospital in Houston
HeartMate I received FDA approval for bridge-to-transplant in 1994
HeartMate II, a continuous-flow pump, gained FDA approval in 2010
Modern LVADs have increased patient survival rates to over 80% at two years

Overview

The left ventricular assist device (LVAD) is a mechanical pump designed to support heart function in patients with severe heart failure. Developed over several decades, the LVAD has evolved from bulky, pulsatile systems to compact, continuous-flow devices.

Its invention marked a turning point in cardiac care, offering life-saving support for patients awaiting heart transplants or those ineligible for transplantation. Today, LVADs are critical tools in managing end-stage heart failure.

1966 marked the first experimental use of an LVAD when Dr. Michael DeBakey implanted a prototype in a patient, demonstrating feasibility.
The first clinically approved LVAD implant occurred in 1984 at The Methodist Hospital in Houston, Texas, using the Novacor device.
The HeartMate I pulsatile pump received FDA approval in 1994 specifically for bridge-to-transplant therapy, improving survival rates significantly.
In 2010, the HeartMate II continuous-flow LVAD received full FDA approval, offering smaller size, greater reliability, and improved patient outcomes.
Modern LVADs like the HeartMate 3, approved in 2017, feature magnetically levitated rotors, reducing complications like stroke and pump thrombosis.

How It Works

An LVAD functions by taking over the pumping action of the left ventricle, ensuring adequate blood flow to the body. It consists of an internal pump, external controller, and power source, working together to sustain cardiac output.

Pump Placement: The LVAD pump is surgically implanted in the apex of the left ventricle and connected to the ascending aorta to propel blood forward.
Internal Cannula: A tube directs blood from the left ventricle into the pump, where it is accelerated by a spinning impeller or rotor mechanism.
Continuous Flow: Modern LVADs use continuous-flow technology, maintaining steady circulation rather than mimicking natural pulsations, increasing efficiency.
External Controller: Worn outside the body, this device monitors pump function, adjusts speed, and alerts patients to potential malfunctions or low battery.
Power Source: External batteries, typically worn on a belt, power the device and last 10–14 hours; patients must carry spares at all times.
Transdermal Cable: A driveline passes through the skin, connecting the internal pump to the external controller and power source, requiring strict hygiene to prevent infection.

Comparison at a Glance

LVAD technology has advanced significantly, with newer models outperforming earlier versions in durability, safety, and patient quality of life.

Model	Year Approved	Type	Survival at 2 Years	Key Features
HeartMate I	1994	Pulsatile	68%	First FDA-approved LVAD; used for bridge-to-transplant
HeartMate II	2010	Continuous-flow	82%	Smaller size; longer durability; reduced stroke risk
HeartMate 3	2017	Continuous-flow	86%	Full maglev technology; lower rates of pump thrombosis
Abbott HVAD	2012	Continuous-flow	79%	Centrifugal design; withdrawn in 2021 due to neurological risks
HeartWare	2014	Continuous-flow	80%	Compact design; implanted near diaphragm; lower profile

The transition from pulsatile to continuous-flow devices has dramatically improved outcomes. Newer models offer better survival, fewer complications, and enhanced mobility, although infection and stroke remain concerns. Continuous-flow systems dominate current use due to reliability and smaller size.

Why It Matters

LVADs have transformed the treatment landscape for end-stage heart failure, offering extended life and improved quality of life for thousands.

Over 30,000 LVADs are implanted annually in the U.S., reflecting their growing role in long-term heart failure management.
Patients with LVADs experience a 50% reduction in heart failure hospitalizations compared to medical therapy alone.
LVADs serve as a bridge to transplant, allowing critically ill patients to survive longer while awaiting donor hearts.
For ineligible transplant candidates, LVADs function as destination therapy, extending life by an average of 5–7 years.
Modern LVADs improve functional status, with over 85% of patients achieving NYHA Class I or II heart failure symptoms post-implant.
Technological advances continue to reduce complications, with newer models showing stroke rates under 10% per year.

As research progresses, fully implantable and wireless LVADs may soon eliminate drivelines and external components, further enhancing patient independence and safety.